|
|
Latest Multiple Myeloma News
Maintenance Therapy with Revlimid Slows Myeloma Progression (6/3/2010)
Maintenance therapy with RevlimidÒ (lenalidomide) slowed disease progression by 54% among patients with multiple myeloma who had undergone high-dose chemotherapy and autologous stem cell transplantation. Interim results of this Phase III study will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (3/24/2010)
Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology.
Complete Remission Predicts for Long Survival in Multiple Myeloma (3/22/2010)
Achieving a complete remission was the dominant prognostic factor for long survival in patients with multiple myeloma, according to a large retrospective review published in Bone Marrow Transplantation.
Benefit of Velcade on Myeloma Survival Added to Prescribing Information (3/5/2010)
The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients with previously untreated multiple myeloma.
Addition of Velcade® and Revlimid® to Autologous Stem Cell Transplantation Produces Promising Results in Older Patients with Multiple Myeloma (1/7/2010)
In a Phase II clinical trial, treatment of older multiple myeloma patients with Velcade® (bortezomib) induction therapy, reduced-intensity tandem autologous stem cell transplantation, and Revlimid® (lenalidomide) consolidation-maintenance therapy produced promising response rates. These results were published in the Journal of Clinical Oncology.
Multiple Myeloma News By Topic
Multiple Myeloma - Stage I/Smoldering MyelomaComplete Remission Predicts for Long Survival in Multiple Myeloma (3/22/2010)
Achieving a complete remission was the dominant prognostic factor for long survival in patients with multiple myeloma, according to a large retrospective review published in Bone Marrow Transplantation.
Benefit of Velcade on Myeloma Survival Added to Prescribing Information (3/5/2010)
The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients with previously untreated multiple myeloma.
Revlimid® Delays Progression of Multiple Myeloma (12/18/2009)
Among multiple myeloma patients who have had an autologous stem cell transplant, additional treatment with Revlimid® (lenalidomide) delays cancer progression. These results were released by the National Cancer Institute.
Pesticides Linked to Precancerous Blood Disorder (6/24/2009)
Individuals who apply pesticides to crops are twice as likely as the general population to develop a precancerous blood disorder called MGUS (monoclonal gammopathy of undetermined significance), which can lead to multiple myeloma, according to the results of a study published in Blood.
Formaldehyde Exposure May Increase Risk of Blood and Lymphatic Cancers (6/23/2009)
Industrial workers who are exposed to formaldehyde may be at an increased risk of dying from blood and lymphatic cancers, particularly myeloid leukemia but also Hodgkin’s lymphoma and multiple myeloma, according to the results of a study published in the Journal of the National Cancer Institute.
Multiple Myeloma - Stages II-IIIMaintenance Therapy with Revlimid Slows Myeloma Progression (6/3/2010)
Maintenance therapy with RevlimidÒ (lenalidomide) slowed disease progression by 54% among patients with multiple myeloma who had undergone high-dose chemotherapy and autologous stem cell transplantation. Interim results of this Phase III study will be presented at the 2010 annual meeting of the American Society of Clinical Oncology.
Kepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (3/24/2010)
Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology.
Complete Remission Predicts for Long Survival in Multiple Myeloma (3/22/2010)
Achieving a complete remission was the dominant prognostic factor for long survival in patients with multiple myeloma, according to a large retrospective review published in Bone Marrow Transplantation.
Benefit of Velcade on Myeloma Survival Added to Prescribing Information (3/5/2010)
The U.S. Food and Drug Administration (FDA) has approved expanded prescribing information for Velcade® (bortezomib). Velcade’s label now includes results from the VISTA study, which show that Velcade improves long-term overall survival among patients with previously untreated multiple myeloma.
Addition of Velcade® and Revlimid® to Autologous Stem Cell Transplantation Produces Promising Results in Older Patients with Multiple Myeloma (1/7/2010)
In a Phase II clinical trial, treatment of older multiple myeloma patients with Velcade® (bortezomib) induction therapy, reduced-intensity tandem autologous stem cell transplantation, and Revlimid® (lenalidomide) consolidation-maintenance therapy produced promising response rates. These results were published in the Journal of Clinical Oncology.
Multiple Myeloma - RecurrentKepivance Reduces Toxicity of High-dose Therapy for Multiple Myeloma (3/24/2010)
Among patients undergoing high-dose therapy and autologous stem cell transplantation for multiple myeloma, a three-day short course of Kepivance® (palifermin) reduces the toxicity of treatment. These results were published in the Annals of Oncology.
Velcade® plus Perifosine Shows Promise in Relapsed or Refractory Multiple Myeloma (1/16/2009)
Among patients with relapsed or refractory multiple myeloma previously treated with Velcade® (bortezomib), 40% responded to treatment with a combination of Velcade and perifosine. The details of this study were presented at the 2008 meeting of the American Society of Hematology on December 9, 2008 in San Francisco.
Preventive Dental Care Reduces Osteonecrosis of the Jaw Associated with Bisphosphonates (8/20/2008)
Patients who undergo preventive dental care prior to receiving therapy with bisphosphonates have a significantly reduced risk of developing osteonecrosis of the jaw. These results were published in an early online publication in the Annals of Oncology.
Multiple Myeloma Treatment Does Not Affect the Outcome of Stem Cell Transplant (4/18/2008)
A recently published study indicates that the type of initial chemotherapy for multiple myeloma has no impact on the outcome of patients who later undergo autologous stem cell transplant. These findings appeared in an early online publication of Bone Marrow Transplantation.
Revlimid® Improves Survival in Relapsed Multiple Myeloma (11/26/2007)
According to two articles recently published in the New England Journal of Medicine, Revlimid® (lenalidomide) improves survival for patients with multiple myeloma that has returned following prior therapies.
|
|
